{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T21:32:09Z","timestamp":1768253529519,"version":"3.49.0"},"reference-count":25,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the key medical professional development plan of Beijing Hospital Authority","award":["ZYLX202124"],"award-info":[{"award-number":["ZYLX202124"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The survival benefits of radical treatment (resection or radiofrequency ablation) combined with splenectomy for primary hepatocellular carcinoma (HCC) in patients with liver-cirrhosis-associated portal hypertension (PH) remain to be clarified. Methods: 96 patients undertaking HCC radical treatment combined with splenectomy (HS group) were retrospectively analyzed, 48 of whom belonged to HCC stage T1 (HSS group). Another 42 patients at stage T1 with PH who received hepatectomy (or radiofrequency ablation) alone (HA group) during the same period served as the control group. Recurrence-free survival (RFS) and overall survival (OS) were compared at each time point between the HSS and HA group. The risk factors affecting early RFS and OS were confirmed through COX multivariate analysis. Results: The median RFS was 22.3 months and the mean median OS was 46 months in the HS group. As such, 1-year, 2-year, 3-year, and 5-year RFS rates in the HSS and HA group were 95% and 81% (p = 0.041), 81% and 67% (p = 0.05), 64% and 62% (p = 1.00), and 29% and 45% (p = 0.10), respectively. Further, 1-year, 3-year, and 5-year OS rates in the HSS and HA group were 98% and 98% (p = 1.00), 79% and 88% (p = 0.50), and 60% and 64% (p = 0.61), respectively. Cox multivariate analysis showed that preoperative irregular anti-viral therapy, Child-Pugh grade B liver function, vascular invasion, and microvascular invasion (MVI) were independent risk factors for early postoperative RFS (within 2 years), and preoperative irregular anti-viral therapy and vascular invasion were independent risk factors for 5-year OS. Conclusions: Radical treatment of HCC combined with synchronous splenectomy, especially applicable to patients with Child-Pugh grade A liver function, can significantly improve early postoperative RFS in patients with stage T1 HCC and liver-cirrhosis-associated portal hypertension, but fail to improve OS.<\/jats:p>","DOI":"10.3390\/cancers14133155","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:07:02Z","timestamp":1656374822000},"page":"3155","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Benefits of Radical Treatments with Synchronous Splenectomy for Patients with Hepatocellular Carcinoma and Portal Hypertension"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4817-585X","authenticated-orcid":false,"given":"Qikun","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of General Surgical Center, Beijing Youan Hospital, Capital Medical University, 8 Xitoutiao, Youwai Street, Fengtai District, Beijing 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Beijing Youan Hospital, Capital Medical University, 8 Xitoutiao, Youwai Street, Fengtai District, Beijing 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuchao","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Hebei Medical University, 89 Donggang Street, Shijiazhuang 050031, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Surgical Center, Beijing Youan Hospital, Capital Medical University, 8 Xitoutiao, Youwai Street, Fengtai District, Beijing 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menglong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgical Center, Beijing Youan Hospital, Capital Medical University, 8 Xitoutiao, Youwai Street, Fengtai District, Beijing 100069, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin. Med. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9997","DOI":"10.1038\/s41598-018-28337-6","article-title":"Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept","volume":"8","author":"Tovoli","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/13543784.2021.1948532","article-title":"Lenvatinib plus pembrolizumab: The next frontier for the treatment of hepatocellular carcinoma?","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/13543784.2021.1972969","article-title":"PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: How can they assist drug clinical trials?","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_5","unstructured":"National Health Care Commission (2022). Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition). Chin. Arch. Gen. Surg., 16, 81\u201396."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2147\/OTT.S87580","article-title":"Simultaneous hepatectomy and splenectomy versus hepatectomy alone for hepatocellular carcinoma complicated by hypersplenism: A meta-analysis","volume":"8","author":"Li","year":"2015","journal-title":"Onco Targets Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"46298","DOI":"10.18632\/oncotarget.17758","article-title":"Synchronous splenectomy and hepatectomy for patients with small hepatocellular carcinoma and pathological spleen-neutrophil to lymphocyte ratio changes can predict the prognosis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jso.25577","article-title":"Is synchronous hepatectomy and splenectomy superior to hepatectomy alone for selected patients with hepatocellular carcinoma and clinically significant portal hypertension?","volume":"120","author":"Xie","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3748\/wjg.v21.i8.2358","article-title":"Synchronous splenectomy and hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A case-control study","volume":"21","author":"Zhang","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"European Association for the Study of The Liver, and European Organisation for Research and Treatment of Cancer (2012). EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. Eur. J. Cancer, 48, 599\u2013641.","DOI":"10.1016\/j.ejca.2011.12.021"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1055\/s-0043-103952","article-title":"EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version)","volume":"38","author":"Dietrich","year":"2017","journal-title":"Ultraschall Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1072-7515(99)00294-X","article-title":"Splenectomy in Patients with Hepatocellular Carcinoma and Hypersplenism","volume":"190","author":"Sugawara","year":"2000","journal-title":"J. Am. Coll. Surg."},{"key":"ref_13","first-page":"1043","article-title":"The role of splenectomy in patients with hepatocellular carcinoma and hypersplenism as an aid to hepatectomy","volume":"90","author":"Takayama","year":"1989","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s00268-017-4232-z","article-title":"Impact of Splenic Volume and Splenectomy on Prognosis of Hepatocellular Carcinoma Within Milan Criteria After Curative Hepatectomy","volume":"42","author":"Takeishi","year":"2018","journal-title":"World J. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/bjs.4776","article-title":"Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism","volume":"92","author":"Chen","year":"2005","journal-title":"Br. J. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.hbpd.2018.01.003","article-title":"Effects of terlipressin versus splenectomy on liver regeneration after partial hepatectomy in rats: What we know so far?","volume":"17","author":"Athanasiou","year":"2018","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_17","first-page":"848","article-title":"Immunological consequences following splenectomy in patients with liver cirrhosis","volume":"18","author":"Hirakawa","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.21037\/atm-20-2229","article-title":"Impact of splenomegaly and splenectomy on prognosis in hepatocellular carcinoma with portal vein tumor thrombus treated with hepatectomy","volume":"9","author":"Chai","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/13645706.2019.1609990","article-title":"Simultaneous radiofrequency ablation combined with laparoscopic splenectomy: A safe and effective way for patients with hepatocellular carcinoma complicated with cirrhosis and hypersplenism","volume":"29","author":"Jia","year":"2020","journal-title":"Minim. Invasive Ther. Allied Technol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jso.25392","article-title":"Synchronous hepatectomy and splenectomy vs hepatectomy for selected patients with hepatocellular carcinoma and clinically significant portal hypertension: A systematic review and meta-analysis","volume":"119","author":"Kong","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9065845","DOI":"10.1155\/2019\/9065845","article-title":"Safety of Simultaneous Hepatectomy and Splenectomy in the Treatment of Hepatocellular Carcinoma Complicated with Hypersplenism: A Meta-analysis","volume":"2019","author":"Liu","year":"2019","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s11605-018-3981-9","article-title":"Benefits of Splenectomy and Curative Treatments for Patients with Hepatocellular Carcinoma and Portal Hypertension: A Retrospective Study","volume":"23","author":"Pei","year":"2019","journal-title":"J. Gastrointest. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12957-016-0954-x","article-title":"Laparoscopic RFA with splenectomy for hepatocellular carcinoma","volume":"14","author":"Hu","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1159\/000509806","article-title":"Microvascular Invasion as a Prognostic Predictor in Hepatocellular Carcinoma: How Accurate Is It?","volume":"9","author":"Huo","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000504193","article-title":"Microvascular Invasion and a Size Cutoff Value of 2 cm Predict Long-Term Oncological Outcome in Multiple Hepatocellular Carcinoma: Reappraisal of the American Joint Committee on Cancer Staging System and Validation Using the Surveillance, Epidemiology, and End-Results Database","volume":"9","author":"Shindoh","year":"2020","journal-title":"Liver Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/13\/3155\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:39:22Z","timestamp":1760139562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/13\/3155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":25,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["cancers14133155"],"URL":"https:\/\/doi.org\/10.3390\/cancers14133155","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]}}}